Skip to content
LATEST
Markets

Palisade Bio director buys 50,000 shares for $50,500

Director Robert Baltera expanded his direct stake by nearly 11% shortly after the biopharmaceutical developer missed quarterly earnings forecasts.

Palisade Bio director buys 50,000 shares for $50,500

Palisade Bio director Robert Baltera purchased 50,000 shares of the biopharmaceutical company for $50,500 on Nov. 17, according to a Securities and Exchange Commission filing.

The transaction increased Baltera's direct holding by 10.82% to 511,904 shares, coming one week after the company posted a wider-than-expected quarterly loss of $0.07 per share.

Baltera acquired the shares at an average price of $1.01 each. Based on the acquisition price, the director's total equity position reached approximately $517,023.

Palisade Bio stock fell $0.02 to $0.93 during mid-day trading on Thursday, hovering near its 52-week low of $0.92 and below its 50-day moving average of $1.41. The company has a market capitalisation of $165.90 million.

The insider purchase followed third-quarter financial results published Nov. 10, when the gastrointestinal therapy developer missed analyst consensus estimates by $0.01. Research analysts expect the firm to post a loss of $0.24 per share for the full fiscal year.

Palisade Bio is developing oral therapies for inflammatory bowel conditions, including PALI-2108 for ulcerative colitis and Crohn's disease, and LB1148 for postoperative bowel recovery. Institutional investors hold 11.79% of the company's shares.

Source: Securities and Exchange Commission Form 4 filing, Nov. 19, 2026.

More stories

Latest news